Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.49 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.49 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.49 |
| ▸ | GCGR | P47871 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6220500 | 0.89 | MAPK14 (0.50) | MAPK14MAPK13CSNK1DCSNK1EMAPK12 | |
| SCHEMBL25222456 | 0.88 | IKBKB (0.49) | MAPK14MAPK13CSNK1DCSNK1EMAPK12 | |
| SCHEMBL27627780 | 0.85 | MAPK14 (0.46) | MAPK14MAPK13CSNK1DCSNK1EMAPK12 | |
| SCHEMBL6375585 | 0.85 | HTR3A (0.55) | MAPK14MAPK13CSNK1DCSNK1EMAPK12 | |
| SCHEMBL6369842 | 0.83 | MAPK14 (0.50) | MAPK14MAPK13CSNK1DCSNK1EMAPK12 | |
| SCHEMBL6371945 | 0.81 | MAPK14 (0.42) | MAPK14MAPK13CSNK1DCSNK1EMAPK12 | |
| SCHEMBL6370946 | 0.79 | MAPK14 (0.43) | MAPK14MAPK13CSNK1DCSNK1EMAPK12 | |
| SCHEMBL25611852 | 0.78 | MAPK14 (0.55) | MAPK14MAPK13CSNK1DCSNK1EMAPK12 | |
| SCHEMBL27608554 | 0.77 | MAPK14 (0.46) | MAPK14MAPK13CSNK1DCSNK1EMAPK12 | |
| SCHEMBL25612980 | 0.77 | MAPK14 (0.48) | MAPK14MAPK13CSNK1DCSNK1EMAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192699-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2023-06-22 | — | — | US | disclosed |
| EP-4126878-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2023-02-08 | — | — | EP | disclosed |
| CN-115335057-A | Method for inhibiting casein kinase | 北京原基华毅生物科技有限公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-115298183-A | Compounds as casein kinase inhibitors | 北京原基华毅生物科技有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-1701069-A | 3,4-disubstituted pyrroles and their for use in treating inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2005-11-23 | — | — | CN | disclosed |
| EP-1549635-A1 | 3,4-DISUBSTITUTED PYRROLES AND THEIR FOR USE IN TREATING INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-07-06 | — | — | EP | disclosed |
| US-20050043331-A1 | Substituted 3-(2,5-disubstituted)pyridyl-4-aryl pyrroles for treating inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
| WO-2004029040-A1 | 3,4-DISUBSTITUTED PYRROLES AND THEIR FOR USE IN TREATING INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043331-A1 | Substituted 3-(2,5-disubstituted)pyridyl-4-aryl pyrroles for treating inflammatory diseases | TNF, TSLP, IRAK1 | MAPK14 240/4885MAPK13 118/4885CSNK1D 808/4885 |
| US-20230192699-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | CSNK2A3, CSNK1A1, CSNK1G3 | MAPK14 76/4885MAPK13 54/4885CSNK1D 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.